Real-Time Continuous Glucose Monitoring in Adolescents and Young Adults With Type 2 Diabetes Can Improve Quality of Life

• Published in: Journal of diabetes science and technology Vol. 18; no. 4; pp. 911 - 919
• Main Authors: Chesser, Hannah, Srinivasan, Shylaja, Puckett, Cassidy, Gitelman, Stephen E., Wong, Jenise C.
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.07.2024
• Subjects: Adolescent; Blood Glucose - analysis; Blood Glucose Self-Monitoring; Continuous Glucose Monitoring; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - psychology; Feasibility Studies; Female; Glycated Hemoglobin - analysis; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Male; Original; Pilot Projects; Quality of Life; Young Adult; lifestyle factors; sensors; type 2 diabetes; continuous glucose monitoring; adolescents; pediatrics
• ISSN: 1932-2968; 1932-3107
• DOI: 10.1177/19322968221139873

Objective: Real-time continuous glucose monitoring (CGM) is effective for diabetes management in cases of type 1 diabetes and adults with type 2 diabetes (T2D) but has not been assessed in adolescents and young adults (AYAs) with T2D. The objective of this pilot interventional study was to assess the feasibility and acceptability of real-time CGM use in AYAs with T2D. Methods: Adolescents and young adults (13-21 years old) with T2D for six months or more and hemoglobin A1c (A1c) greater than 7%, on any Food and Drug Administration–approved treatment regimen, were included. After a blinded run-in period, participants were given access to a real-time CGM system for 12 weeks. The use and acceptability of the real-time CGM were evaluated by sensor usage, surveys, and focus group qualitative data. Results: Participants’ (n = 9) median age was 19.1 (interquartile range [IQR] 16.8-20.5) years, 78% were female, 100% were people of color, and 67% were publicly insured. Baseline A1c was 11.9% (standard deviation ±2.8%), with median diabetes duration of 2.5 (IQR 1.4-6) years, and 67% were using insulin. Seven participants completed the study and demonstrated statistically significant improvement in diabetes-related quality of life, with the mean Pediatric Quality of Life inventory (PedsQL) diabetes score increasing from 70 to 75 after using CGM (P = .026). Focus group results supported survey results that CGM use among AYAs with T2D is feasible, can improve quality of life, and has the potential to modify behavior. Conclusion: Real-time CGM is feasible and acceptable for AYAs with T2D and may improve the quality of life of patients with diabetes. Larger randomized controlled trials are needed to assess the effects on glycemic control and healthy lifestyle changes.